Jason Haas, serving as a director at Ligand Pharmaceuticals Inc. (NASDAQ: LGND), completed a substantial divestment of company equity on June 12, 2026. Regulatory filings indicate the transaction involved the liquidation of common stock valued at approximately $1,651,320. This sale was facilitated through the exercise of stock options, resulting in the disposal of 6,461 shares.
The timing of Haas's transaction coincides with Ligand's stock performance near its 52-week high of $259. Over the preceding year, the equity has delivered a 120% return. Market analysis suggests the stock may be trading above its intrinsic fair value, though detailed valuation metrics require subscription access.
Haas's sales were executed in two distinct tranches. The first tranche involved 3,000 shares sold at a weighted-average price of $255.0113 per share. Individual transactions within this block occurred within a narrow price band of $255.0000 to $255.2900. The second tranche consisted of 3,461 shares, which were liquidated at a weighted-average price of $256.0781 per share. These shares traded between $256.0000 and $256.5100 during the execution period.
Before initiating these sales, Haas acquired 4,000 shares of Ligand Pharmaceuticals common stock. This acquisition was completed by exercising non-qualified stock options at a price of $51.56 per share, totaling $206,240. These options originated from a grant reported on June 29, 2022, and were subsequently adjusted following the separation of OmniAb Inc. from the issuer. Following the recent divestments, Haas directly retains ownership of 4,981 shares of Ligand Pharmaceuticals common stock. The regulatory filing was executed by Andrew Reardon, Attorney-in-Fact for Jason Haas, on June 15, 2026.
In parallel with the insider transaction, Ligand Pharmaceuticals reported its first-quarter 2026 earnings results, which missed analyst expectations. The company reported an adjusted earnings per share (EPS) of $1.63, falling short of the anticipated $1.84. This discrepancy represents an 11.41% negative surprise. Revenue also underperformed forecasts, coming in at $51.72 million compared to the expected $59.07 million, marking a 12.44% revenue shortfall.
Furthermore, Ligand Pharmaceuticals has amended its merger agreement with XOMA Royalty Corporation. The amendment formally includes XOMA Royalty Holdings Corporation as a party to the agreement. Under the revised terms, Flex Merger Sub, Inc., a wholly owned subsidiary of Ligand, will merge with and into HoldCo. HoldCo is a newly formed Nevada corporation and a wholly owned subsidiary of XOMA Royalty. Following the completion of the merger, HoldCo will continue as a wholly owned subsidiary of Ligand. These structural changes and financial results highlight significant operational adjustments for the company.